Zynex Announces 2021 Fourth Quarter and Full Year Earnings

Rhea-AI Summary

Zynex reported strong financial results for Q4 and full year 2021, with a 63% increase in annual revenue to $130.3 million and a 58% rise in Q4 revenue to $40.4 million. Net income surged 398% in Q4 to $8.9 million, yielding a diluted EPS of $0.23. The company achieved its 6th consecutive year of profitability with a cash balance of $42.6 million. For 2022, revenue guidance is set between $150-$170 million, despite challenges in hiring sales representatives due to labor market conditions.

Positive

• 2021 revenue increased 63% to $130.3 million.
• Net income rose 88% to $17.1 million for the full year.
• Adjusted EBITDA increased 95% to $26.7 million.
• Q4 revenue grew 58% year over year to $40.4 million.
• Gross margins improved to 82%, exceeding guidance.
• Sixth consecutive year of profitability reported.

Negative

• Order growth expected to be modest due to labor market challenges.
• Full year 2022 revenue guidance reflects slower sales force expansion.
• Operating expenses anticipated to increase by approximately $5 million in 2022.

ENGLEWOOD, Colo., Feb. 24, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 2021.

• 2021 Full Year
• Revenue increased 63% year over year to $130.3 million
• Orders increased 89%
• Net income increased 88% to $17.1 million; Diluted EPS of $0.44
• Adjusted EBITDA increased 95% to $26.7 million
• 6^th straight year of profitability
• $42.6 million cash balance
• 2021 Fourth Quarter
• Revenue increased 58% year over year to $40.4 million
• Orders increased 18%
• Net income increased 398% to $8.9 million; Diluted EPS $0.23
• Adjusted EBITDA increased 276% to $13.0 million

Fourth Quarter Financial Results Summary:

For the fourth quarter, the Company reported net revenue of $40.4 million, a 58% increase over fourth quarter of 2020. Gross margins were 82%, better than previous guidance ranging between 75% and 80%. Net income was $8.9 million, a 398% increase from Q4 2020.

As of December 31, 2021, the Company had working capital of $59.8 million, compared to $52.9 at the close of last fiscal year. Cash on hand was $42.6 million at the end of the fourth quarter, up over $7.2 million, or 20%, from Q3.

President and CEO Commentary:

"We are thrilled to announce another consecutive quarter of record growth. We recognized the highest quarterly revenues in the Company's history, and are poised for further expansion supported by Zynex's financial health," said Thomas Sandgaard, President and CEO. "Adjusted EBITDA margins continue to increase and represent our vigilance for growing top line revenue and managing operational efficiencies. Labor market dynamics have made attracting qualified sales reps and employees for our corporate headquarters in Colorado difficult. Therefore, we expect order growth to be fairly modest until the job market eventually normalizes and we are able to add additional reps to our sales force."

First Quarter and Full Year 2022 Guidance

Full year 2022 revenue is estimated in the range of $150-$170 million and Adjusted EBITDA between $25 and $35 million. The revenue range is based on the current labor shortage and growing the sales force at a slower cadence than previously anticipated. Adjusted EBITDA is impacted by increased operating expenses to support the Monitoring Division (ZMS) as the Kestrel products are prepared for FDA submission and the fluid monitor is readied for the market. These initiatives are currently estimated at an approximately $5M OPEX increase over 2021. Profitability is expected to grow as sales reps become more efficient, further highlighting the expected EBITDA growth in 2022.

First quarter 2022 revenue is estimated to range between $29 and $32 million, an increase of approximately 26% from 1Q21. Primarily affected by the resetting of health insurance deductibles in the beginning of a calendar year, seasonably lower revenues in the first quarter are a historical trend for Zynex and an industry norm.

First quarter 2022 Adjusted EBITDA is estimated to range between $3.0 and $4.5 million, an increase of approximately 1072% from 1Q21.

Sales and profit will ramp through the remainder of 2022 and bolster expected growth for the full year.

Conference Call and Webcast Details

Thursday, February 24, 2022 at 2:15 p.m. MT / 4:15 p.m. ET

To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast: https://www.webcaster4.com/Webcast/Page/1487/44417   

US Participant Dial In (TOLL FREE): 1-844-825-9790
International Participant Dial In: 1-412-317-5170
Canada Participant Dial In (TOLL FREE): 1-855-669-9657

Non-GAAP Financial Measures
Zynex reports its financial results in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information in the form of Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, other income/expense, stock compensation, restructuring and non-cash lease charges). Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of available earnings. Non-GAAP financial measures should not be considered in isolation from, or as an alternative to, the financial information prepared in accordance with GAAP.

About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com

Safe Harbor Statement
This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.  The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including, but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact
Gilmartin Group
650 Fifth Ave., Suite 2720
New York, NY 10019
IR@zynex.com

ZYNEX, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands) (unaudited)
	December 31,			December 31,
	2021			2020
ASSETS
Current assets:
Cash		$         42,612		$          39,173
Accounts receivable, net		28,632		13,837
Inventory, net		10,756		8,635
Prepaid expenses and other		689		1,378
Total current assets		82,689		63,023
Property and equipment, net		2,186		1,925
Operating lease asset		16,338		5,993
Finance lease asset		389		321
Deposits		585		347
Intangible assets, net of accumulated amortization		9,975		-
Goodwill		20,401		-
Deferred income taxes		711		566
Total assets		$       133,274		$          72,175
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses		4,739		4,709
Cash dividends payable		3,629		8
Operating lease liability		2,859		2,051
Finance lease liability		118		77
Income taxes payable		2,296		280
Current portion of debt		5,333		-
Accrued payroll and related taxes		3,897		2,992
Total current liabilities		22,871		10,117
Long-term liabilities:
Long-term portion of debt, less issuance costs		10,605		-
Contingent consideration		9,700		-
Operating lease liability		15,856		4,920
Finance lease liability		317		283
Total liabilities		59,349		15,320
Stockholders' equity:
Common stock		41		36
Additional paid-in capital		80,397		37,235
Treasury stock		(6,513)		(3,846)
Retained earnings		-		23,430
Total stockholders' equity		73,925		56,855
Total liabilities and stockholders' equity		$       133,274		$          72,175

 

ZYNEX, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands except per share data) (unaudited)
	For the Three Months Ended December 31,				For the Years Ended December 31,
	2021		2020		2021		2020
NET REVENUE
Devices	$      13,349		$      8,243		$      36,613		$      21,269
Supplies	27,017		17,362		93,688		58,853
Total net revenue	40,366		25,605		130,301		80,122
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies	7,331		5,659		27,321		17,417
Sales and marketing	13,628		12,320		54,290		34,133
General and administrative expense	7,821		5,328		26,324		18,323
Total costs of revenue and operating expenses	28,780		23,307		107,935		69,873
Income from operations	11,586		2,298		22,366		10,249
Other income (expense)
Loss on disposal of non-controlling interest	-		(77)		-		(77)
Interest expense	(23)		(5)		(95)		(19)
Other income (expense), net	(23)		(82)		(95)		(96)
Income from operations before income taxes	11,563		2,216		22,271		10,153
Income tax expense	2,669		428		5,168		1,079
Net Income	$      8,894		$      1,788		$      17,103		$      9,074
Net income per share:
Basic	$        0.23		$       0.05		$          0.45		$       0.24
Diluted	$        0.23		$       0.05		$          0.44		$       0.24
Weighted average basic shares outstanding	38,411		38,258		38,317		37,256
Weighted average diluted shares outstanding	39,170		39,199		39,197		38,438

 

ZYNEX, INC.
Reconciliation of GAAP to Non-GAAP Measures
(in thousands)
(unaudited)
	For the Three Months Ended December 31,				For the Years Ended December 31,
	2021		2020		2021		2020
Adjusted EBITDA:
Net income	$                8,894		$               1,788		$                  17,103		$                         9,074
Depreciation and Amortization*	214		272		925		742
Stock-based compensation expense	589		875		1,630		2,681
Restructuring/severance**	-		-		318		-
Interest expense and other, net	23		82		95		96
Non-cash lease expense ***	572		-		1,428		-
Income tax expense	2,669		428		5,168		1,079
Adjusted EBITDA	$               12,961		$               3,445		$           26,667		$                       13,672
% of Net Revenue	32%		13%		20%		17%

 

* Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold.

** Severance of former COO Giusseppe Papandrea which was fully expensed in Q1-2021

*** Amount expensed on new company headquarters on which no payments are due until 2022

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-2021-fourth-quarter-and-full-year-earnings-301490089.html

SOURCE Zynex

FAQ

What were Zynex's fourth quarter 2021 earnings results?

Zynex reported a Q4 2021 revenue of $40.4 million, a 58% increase, and net income of $8.9 million, a 398% increase from Q4 2020.

What is Zynex's revenue guidance for full year 2022?

Zynex estimates its 2022 revenue to be between $150 million and $170 million.

How did Zynex's net income perform in 2021?

Zynex's net income for the full year 2021 increased by 88% to $17.1 million.

What challenges is Zynex facing regarding order growth?

Zynex expects modest order growth due to difficulties in hiring qualified sales representatives.

What is Zynex's cash balance as of December 31, 2021?

Zynex reported a cash balance of $42.6 million at the end of Q4 2021.